risankizumab vs tildrakizumab

NCT02684370 · Phase 3 · completed

This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.

NCT01729754 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

NCT04314544 · Phase 3 · completed

The study randomized 508 participants to tildrakizumab or placebo, with outcome assessors masked, and used the clinical ACR20 response as its primary endpoint. However, no results are posted, so whether the primary endpoint was met or missed is unknown.